SAN FRANCISCO, Feb. 3 /PRNewswire/ -- The US market for the drug treatment of cancer pain in 2008 is valued at $3.1 billion, according to US Cancer Pain, a report released today by WWMR, Inc. The cancer pain market is dominated by opioid drugs, a trend expected to continue throughout the next decade. The increasing number of cancer pain patients will be the primary driver of market value during the forecast period.
Few of the many drugs in development for pain conditions are seeking regulatory approval for cancer pain. Of these, most are reformulations of fentanyl or other opioids, using novel delivery devices or as combination therapies. Reformulations of existing opioids are unlikely to capture market share unless they can compete economically with older agents that are already available on payer-approved formularies.
Today, half of the 4.1 million cancer patients in the US experience pain. More than 600,000, among these, experience moderate-to-severe pain. WWMR estimates that the cancer pain market will be valued at $5.3 billion in 2018, based on a patient population of more than 2.5 million cancer pain patients. While most pain is the result of tissue damage caused by the tumor, some cancer pain is due to the effects of chemotherapy, radiation or surgery; moreover, 25% of patients experience more than one type of cancer pain.
WWMR provides estimates for 2008 and projections to 2018 for SEVEN types of cancer pain: tumor-related, treatment-related, neuropathic, breakthrough pain, malignant bone pain, visceral pain and soft-tissue pain. Interviews with oncologists and pain clinicians, as well as data from WWMR's US Pain Clinic Monitor provide additional perspective on the cancer pain market. WWMR's US Pain Clinic Monitor is an audit of more than 100 pain clinics that includes prescribing data on cancer pain and 26 other pain indications.
Worldwide, only 25 agents are in active cl
|SOURCE WWMR, Inc.|
Copyright©2009 PR Newswire.
All rights reserved